AUPH

Aurinia Pharmaceuticals Inc. · NASDAQ

Sector Health Technology
Industry Biotechnology
Website auriniapharma.com
Employees(FY) 300
ISIN CA05156V1022

Performance

-2.74%

-14.83%

+6.11%

+38.97%

-13.03%

YTD

+3.58%

Profile

Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.

Advanced Technical Analysis

Technical Analysis of AUPH 2025-02-03

The stock indicators reflect a predominantly bearish sentiment, with the Moving Average Score at 16 and the Technical Score at 19, both indicating weak performance. The Oscillators Score of 46 suggests a neutral stance, but overall, the combined scores point towards a lack of bullish momentum in the market.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of AUPH

Stock Rank

Recent News & Updates

2024-06-16 16:46
Strength Seen in Aurinia (AUPH): Can Its 5.6% Jump Turn into More Strength?(Zacks)
2024-06-14 12:16
Aurinia Announces 2024 Annual General Meeting Results(Business Wire)
2024-06-14 00:16
Aurinia Announces 2024 Annual General Meeting Results(Businesswire)
2024-06-08 09:25
We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) CEO For Now(Simply Wall St.)
2024-06-05 06:00
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024(Business Wire)
2024-06-04 18:00
Aurinia Presents Safety and Efficacy Profile of LUPKYNIS for People with Lupus Nephritis at European Alliance of Associations for Rheumatology (EULAR) Congress 2024(Businesswire)
2024-06-04 17:30
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce(Business Wire)
2024-06-04 05:30
Aurinia Addresses Dubious Proposals Put Forth by Lucien Selce(Businesswire)
2024-06-03 18:30
Aurinia Provides Update on Proxy Statement(Business Wire)
2024-05-30 06:00
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference(Business Wire)
2024-05-29 18:00
Aurinia Will Attend 2024 Jefferies Global Healthcare Conference(Businesswire)
2024-05-26 09:53
Shareholders in Aurinia Pharmaceuticals (NASDAQ:AUPH) have lost 64%, as stock drops 9.5% this past week(Simply Wall St.)
2024-05-14 06:00
Analysis Showing LUPKYNIS® is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation’s Spring Clinical Meeting 2024(Business Wire)
2024-05-13 18:00
Analysis Showing LUPKYNIS is a Cost-Effective Treatment for Lupus Nephritis Presented at National Kidney Foundation's Spring Clinical Meeting 2024(Businesswire)
2024-05-09 06:00
Aurinia Presents Data Reinforcing LUPKYNIS® Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024(Business Wire)
2024-05-08 18:00
Aurinia Presents Data Reinforcing LUPKYNIS Safety and Efficacy for People with Lupus Nephritis at Congress of Clinical Rheumatology East 2024(Businesswire)
2024-05-07 09:55
How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%(Zacks)
2024-05-07 06:00
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference(Business Wire)
2024-05-06 21:55
How Much Upside is Left in Aurinia (AUPH)? Wall Street Analysts Think 96.51%(Zacks)
2024-05-06 18:00
Aurinia Will Attend 2024 RBC Capital Markets Global Healthcare Conference(Businesswire)
2024-05-03 13:02
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Call Transcript(Insider Monkey)
2024-05-03 01:02
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q1 2024 Earnings Call Transcript(Insidermonkey)
2024-05-02 07:10
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates(Zacks)
2024-05-02 06:10
Aurinia: Q1 Earnings Snapshot(Associated Press Finance)
2024-05-02 06:00
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results(Business Wire)
2024-05-01 22:56
AUPH Stock Earnings: Aurinia Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024(Investorplace)
2024-05-01 19:10
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates(Zacks)
2024-05-01 18:00
Aurinia Pharmaceuticals Reports First Quarter 2024 Financial and Operational Results(Businesswire)
2024-05-01 06:00
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month(Business Wire)
2024-04-30 18:00
Aurinia Underscores Enduring Commitment to People Living with Lupus Nephritis Through Innovative Advocacy and Education Initiatives for Lupus Awareness Month(Businesswire)

Page 3 of 8

previous next

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.